Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Next Previous
Trial Profile

A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idelalisib (Primary) ; Bendamustine; Bortezomib; Chlorambucil; Everolimus; Fludarabine; Lenalidomide; Ofatumumab; Rituximab
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Gilead Sciences

Most Recent Events

  • 07 Jun 2016 Results of post-hoc analysis of this and other trials (n=1073) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
  • 08 Dec 2015 Results of post-hoc analysis (n=494) of this and other three trial (see profile 59751, 214177 and 35836) were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
  • 02 Jun 2015 Long-term results in patients with chronic lymphocytic leukaemia presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top